Compare VNDA & VMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VNDA | VMD |
|---|---|---|
| Founded | 2002 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 361.4M | 465.4M |
| IPO Year | 2005 | 2018 |
| Metric | VNDA | VMD |
|---|---|---|
| Price | $5.15 | $8.79 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $14.90 | N/A |
| AVG Volume (30 Days) | ★ 618.5K | 269.0K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.14 |
| EPS | N/A | ★ 0.13 |
| Revenue | $216,105,000.00 | ★ $270,280,000.00 |
| Revenue This Year | $21.35 | $17.88 |
| Revenue Next Year | $37.40 | $14.98 |
| P/E Ratio | ★ N/A | $68.46 |
| Revenue Growth | 8.72 | ★ 20.52 |
| 52 Week Low | $4.27 | $6.05 |
| 52 Week High | $9.91 | $12.61 |
| Indicator | VNDA | VMD |
|---|---|---|
| Relative Strength Index (RSI) | 46.21 | 39.77 |
| Support Level | $4.94 | $8.52 |
| Resistance Level | $5.62 | $8.94 |
| Average True Range (ATR) | 0.17 | 0.20 |
| MACD | -0.01 | 0.08 |
| Stochastic Oscillator | 28.57 | 39.25 |
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Viemed Healthcare Inc is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women's health products and services. The Company's primary service offerings focus on effective in-home treatment, with clinical practitioners providing therapy and counseling to patients in their homes using cutting-edge technology. The company generates the majority of its revenue from medical equipment rental, sales, and supply.